Novel method for simultaneous quantification of phenotypic resistance to maturation, protease, reverse transcriptase, and integrase HIV inhibitors based on 3'Gag(p2/p7/p1/p6)/PR/RT/INT-recombinant viruses: a useful tool in the multitarget era of antiretroviral therapy.

doi:10.1128/AAC.00396-11

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Novel method for simultaneous quantification of phenotypic resistance to maturation, protease, reverse transcriptase, and integrase HIV inhibitors based on 3'Gag(p2/p7/p1/p6)/PR/RT/INT-recombinant viruses: a useful tool in the multitarget era of antiretroviral therapy.

Antimicrobial agents and chemotherapy - 1 Aug 2011

Weber Jan, Vazquez Ana C, Winner Dane, Rose Justine D, Wylie Doug, Rhea Ariel M, Henry Kenneth, Pappas Jennifer, Wright Alison, Mohamed Nizar, Gibson Richard, Rodriguez Benigno, Soriano Vicente, King Kevin, Arts Eric J, Olivo Paul D, Quiñones-Mateu Miguel E

Abstract excerpt

Twenty-six antiretroviral drugs (ARVs), targeting five different steps in the life cycle of the human immunodeficiency virus type 1 (HIV-1), have been approved for the treatment of HIV-1 infection. Accordingly, HIV-1 phenotypic assays based on common cloning technology currently employ three, or possibly four, different recombinant viruses. Here, we describe a system to assess HIV-1 resistance to all drugs...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Multiple, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, pol

Share to HIV Integrase Inhibitors

Share to HIV Protease Inhibitors

Share to HIV Reverse Transcriptase

Share to Reverse Transcriptase Inhibitors

Share to Ribonuclease H

Share to Sequence Analysis, RNA

Source

Open in PubMed Open full text

Identifiers

PMID: 21628544
DOI: 10.1128/AAC.00396-11
PMCID: PMC3147656

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel method for simultaneous quantification of phenotypic resistance to maturation, protease, reverse transcriptase, and integrase HIV inhibitors based on 3'Gag(p2/p7/p1/p6)/PR/RT/INT-recombinant viruses: a useful tool in the multitarget era of antiretroviral therapy.PMID 21628544Read ↗

A single-loop recombinant pseudotyped-virus-based assay to detect HIV-1 phenotypic resistance.Semantic proximity Read ↗

Quantitative evaluation of the recombinant HIV-1 phenotype to protease inhibitors by a single-step strategy.Semantic proximity Read ↗

Phenotypic analysis of the sensitivity of HIV-1 to inhibitors of the reverse transcriptase, protease, and integrase using a self-inactivating virus vector system.Semantic proximity Read ↗

Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors.Semantic proximity Read ↗

A Novel Yeast-Based Recombination Method to Clone and Propagate Diverse HIV-1 IsolatesSemantic proximity Read ↗

A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs.Semantic proximity Read ↗

Agreement between an in-house replication competent and a reference replication defective recombinant virus assay for measuring phenotypic resistance to HIV-1 protease, reverse transcriptase, and integrase inhibitors.Semantic proximity Read ↗

A simple and cost-saving phenotypic drug susceptibility testing of HIV-1.Semantic proximity Read ↗

Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assaySemantic proximity Read ↗

A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1.Semantic proximity Read ↗

Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene.Semantic proximity Read ↗

Development of a phenotypic susceptibility assay for HIV-1 integrase inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.